#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 11

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 968
countries: 28
conditions: 2 103

3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Multiple sclerosis

Recruiting

Registered drug

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug

France

Participants:18–64 years
Substances:Ocrelizumab

Contact Research Centre

Crohn's disease

Recruiting

Investigational

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:ICOTROKINRA

Contact Research Centre

Colitis ulcerative

Recruiting

Investigational

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:ICOTROKINRA

Contact Research Centre

Pancreatic carcinoma metastatic+1

Recruiting

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine

Contact Research Centre

Allogenic stem cell transplantation

Recruiting

Registered drugNo placebo

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Blinatumomab

Contact Research Centre

Sepsis

Recruiting

Registered drugNo placebo

Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anakinra

Contact Research Centre

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Recruiting

Investigational

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Investigational

France

Participants:18–64 years · 65+ years
Substances:Ro7790121

Contact Research Centre

Trisomy 21

Recruiting

Investigational

Study of AEF0217 compared to placebo for improving behavior and thinking skills in adults and older adolescents with Down syndrome

Investigational

France

Participants:0–17 years · 18–64 years
Substances:1-((3S,8S,9S,10R,13S,14S,17S)3-BENZYLOXY-10,13,17-TRIMETHYL-2,3,4,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1HCYCLOPENTA[A]PHENANTHRENE-17-YL)ETHAN-1-ONE

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Hypertrophic cardiomyopathy+1

Recruiting

Investigational

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

France

Participants:18–64 years · 65+ years

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:AB521

Contact Research Centre

Breast cancer+2

Recruiting

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capivasertib

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.